Helixmith Participates in 'Bio Europe 2021'

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 22nd that it will participate in ‘BIO Europe 2021,’ which will be held for four days starting from the 25th. At this event, the company plans to hold partnership meetings with major global big pharma companies to discuss possibilities for joint research and technology transfer.

BIO Europe is the largest bio conference in Europe, celebrating its 27th edition this year. Following last year, the event will be held online in a non-face-to-face format due to COVID-19. More than 2,600 pharmaceutical and bio industry professionals and institutional investors from 50 countries worldwide will participate to share the latest bio research achievements and development technologies.

Helixmith will introduce its platform technology and expertise in the gene therapy field, the excellence of ‘Engensis (VM202),’ the latest clinical development status, and future clinical development strategies.

Yoo Seung-shin, CEO of Helixmith, said, “This year, the Engensis (VM202) DPN Phase 3-1 trial was selected as a ‘notable clinical result in Q1 2021’ by Nature Biotechnology, and ongoing clinical trials such as ALS Phase 2a in the US and Korea, and CMT Phase 1/2a in Korea are progressing smoothly. Since various global bio companies are attending, we expect business partnerships including collaborations.”

He added, “Although global business is not easy due to COVID-19, we will take steady participation in digital conferences as an opportunity to grasp global trends and maintain continuous communication.”

‘Engensis (VM202),’ developed by Helixmith, is a plasmid DNA gene therapy that expresses the HGF protein. It does not simply manage pain but targets the root causes of neuropathy through angiogenesis and nerve regeneration effects. The US FDA recognized the scientific and clinical results of Engensis (VM202) and designated it as a Regenerative Medicine Advanced Therapy (RMAT) in 2018.